Contineum Therapeutics (CTNM) Common Equity (2023 - 2026)

Contineum Therapeutics' Common Equity history runs 4 years deep, the most recent figure standing at $250.0 million for Q1 2026.

• On a quarterly basis, Common Equity rose 35.33% year-over-year to $250.0 million in Q1 2026; TTM through Mar 2026 was $250.0 million, a 35.33% increase from a year earlier, with the FY2025 full-year figure at $261.0 million, up 31.77% from the prior year.
• Common Equity declined to $250.0 million in Q1 2026 per CTNM's latest filing, from $261.0 million in the prior quarter.
• Across five years, Common Equity topped out at $261.0 million in Q4 2025 and bottomed at -$97.5 million in Q1 2023.
• The 4-year median for Common Equity is $180.5 million (2025), against an average of $101.2 million.
• Across the five-year window, Common Equity surged 492.38% in 2024 and decreased 21.2% in 2025, its largest moves.
• Year by year, Common Equity stood at -$67.9 million in 2023, then surged by 391.55% to $198.1 million in 2024, then jumped by 31.77% to $261.0 million in 2025, then fell by 4.19% to $250.0 million in 2026.
• Per Business Quant, the three latest CTNM Common Equity figures stand at $250.0 million (Q1 2026), $261.0 million (Q4 2025), and $180.5 million (Q3 2025).